INSIGHTS ON DRUG DEVELOPMENT

DRUG DEVELOPMENT SOLUTIONS

  • Nanoform’s proprietary bionanoparticle technology can deliver large-molecule drug particles as small as 50 nm while retaining biological activity. This can not only enable more patient-friendly approaches to drug delivery, but also potentially higher loads of active ingredients.

  • Learn about a single-use automated filtration system designed to deliver robust process control during this critical downstream step.

  • Curia was the first CRO to provide contract medicinal chemistry services to the pharmaceutical industry.

  • Enhance therapeutic success by optimizing N-glycan profiles with titratable formulations tailored to meet your bioproduction needs.

  • Nanoform’s GMP facility utilizes its award-winning Controlled Expansion of Supercritical Solutions (CESS®) technology for the manufacture of API nanoparticles to GMP standards.